News
VBIV
0.5900
-3.04%
-0.0185
Weekly Report: what happened at VBIV last week (0415-0419)?
Weekly Report · 3d ago
PERCEPTIVE ADVISORS LLC REPORTS 4.4% STAKE IN VBI VACCINES AS OF APRIL 16 - SEC FILING
Reuters · 04/17 20:28
PERCEPTIVE ADVISORS LLC - HAD PREVIOUSLY REPORTED 5.8% STAKE IN VBI VACCINES AS OF NOV 17, 2023
Reuters · 04/17 20:28
VBI VACCINES INC <VBIV.O>: RAYMOND JAMES CUTS TARGET PRICE TO $5 FROM $6
Reuters · 04/17 11:20
U.S. RESEARCH ROUNDUP-3M, J&J, Nuvalent
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. 3M, J&J and Nuvalent are among the companies. Analysts also raise their targets on Amazon, Tractor Supply, UnitedHealth Group and Amgen. NEW: 3M cuts its target price to $110 from $118; 10X Genomics cuts target price.
Reuters · 04/17 07:48
VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023
VBI Vaccines reported earnings per share of -1 cent for the fourth quarter of 2023. The company reported revenue of $853,000. This was 84.09% worse than the analyst estimate of $5.36 million. VBI reported results for the last quarter of 2013.
Investorplace · 04/16 17:52
VBI Vaccines FY Non-GAAP EPS of $3.96
VBI Vaccines reports FY Non-GAAP EPS of $3.96. Net Revenue for the full year 2023 were $8.7M as compared to $1.1M for the same period in 2022. ETVBI Vaccine Inc. (VBIV) stock.
Seeking Alpha · 04/16 15:53
VBI Vaccines Inc reports results for the quarter ended in December - Earnings Summary
VBI Vaccines Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 1 cent per share. Revenue rose 191.1% to $853.00 thousand from a year ago. The average analyst rating on the shares is "buy"
Reuters · 04/16 13:08
VBI Vaccines Soars with Hepatitis B Vaccine Success
TipRanks · 04/16 12:49
*VBI Vaccines 2023 Loss/Shr $3.96 >VBIV
Dow Jones · 04/16 12:02
Press Release: VBI Vaccines Reports Full Year 2023 Financial Results
VBI Vaccines reports full year 2023 financial results. PreHevbrio global net revenue increased 234% year-over-year from 2022 to 2023. Preliminary 2024 pre-hebrio U.S. Sales demonstrate continued growth with 65% of 2023 full-year volume sold in Q1 2024.
Dow Jones · 04/16 12:02
Press Release: VBI Vaccines Reports Full Year -2-
VBI's development expenses for pan-coronavirus and GBM candidates were down due to timing of clinical studies of each candidate. The company's net loss and net loss per share for the year 2023 was $92.8 million. VBI's net cash used in operating activities was down to $60.9 million.
Dow Jones · 04/16 12:02
*VBI Vaccines 2023 Research and Development Expenses $9.3M >VBIV
Dow Jones · 04/16 12:01
*VBI Vaccines 2023 Rev $8.7M >VBIV
Dow Jones · 04/16 12:01
VBI VACCINES REPORTS FULL YEAR 2023 FINANCIAL RESULTS
Reuters · 04/16 12:00
Weekly Report: what happened at VBIV last week (0408-0412)?
Weekly Report · 04/15 09:47
VBI Vaccines Completes $2 Million Offering
TipRanks · 04/11 20:37
VBI Vaccines Raises $1.7 Million in Direct Share Offering
TipRanks · 04/11 20:24
VBI VACCINES ANNOUNCES CLOSING OF $2 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 04/11 20:05
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Fastenal shares dipped 6.7% to $69.73 on Thursday. The company reported worse-than-expected first-quarter financial results. Rallybio Corporation shares climbed 89.6% after company announced a collaboration with Johnson & Johnson. Rent the Runway, Inc. Shares jumped 74.5% after the company reported mixed fourth-quarter results.
Benzinga · 04/11 17:33
More
Webull provides a variety of real-time VBIV stock news. You can receive the latest news about Vbi Vaccines through multiple platforms. This information may help you make smarter investment decisions.
About VBIV
VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.